logo

For the Inventor, By the Inventor

Lebanon, NJ, United States of America

Cynthia Anne Fink

This inventor holds 23 USPTO granted patents and 2 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Novartis Ag, Rhone-Poulenc Rorer Pharmaceuticals Inc., Lexicon Pharmaceuticals, Inc.. Active years: 1993-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Cynthia Anne Fink. Retrieved from https://idiyas.com/inventor/cynthia-anne-fink

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 23

% Patents Active = 87.0

 

Average Co-Inventor Count = 1.8

ph-index = 7

Forward Citations = 537(Granted Patents)


Location History:

  • Doylestown, PA (US) (1993 - 1994)
  • Lebanon, PA (US) (1997)
  • Lebanon, NJ (US) (1995 - 2014)

Company Filing History:

goldMedal10 out of 3,978 
 
Novartis Ag
 patents
silverMedal5 out of 111 
 
Rhone-Poulenc Rorer Pharmaceuticals Inc.
 patents
bronzeMedal4 out of 89 
 
Lexicon Pharmaceuticals, Inc.
 patents
4. 3 out of 6,858 
 
Ciba-Geigy Corporation
 patents
5. 2 out of 3,745 
 
Bristol-Myers Squibb Compnay
 patents
6. 1 out of 166 
 
Novartis Corporation
 patents
where one patent can have more than one assignee

Years Active: 1993-2014

Loading Chart...
Loading Chart...
Areas of Expertise:
Multicyclic Compounds
G Protein-Coupled Receptor
Thiazolopyrazoles
ACE Inhibitors
NEP Inhibitors
Dipeptide Derivatives
Thiol Inhibitors
Cyclic Amino Acids
Cardioprotective Compounds
Anti-Ischemic Properties
Heteroaryl Substituted Compounds
Amino Acid Derivatives
23 patents (USPTO):Explore Patents
1. 8772291 - Multicyclic compounds and methods of their use (2014-07-08),
2. 8497271 - Modulators of G protein-coupled receptor 88 (2013-07-30),
3. 8426414 - Modulators of G protein-coupled receptor 88 (2013-04-23),
4. 7300949 - Thiazolopyrazoles and methods of their use (2007-11-27),
5. 7071169 - Pyrane derivatives as both ACE-and NEP-inhibitors (2006-07-04),
6. 6992105 - Dipeptide derivatives (2006-01-31),
7. 6777443 - Dipeptide derivatives (2004-08-17),
8. 6689801 - Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme (2004-02-10),
9. 6613782 - Certain thiol inhibitors of endothelin-converting enzyme (2003-09-02),
10. 6426354 - Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme (2002-07-30),
11. 6423727 - Certain thiol inhibitors of endothelin-converting enzyme (2002-07-23),
12. 6201133 - Certain cyclic thio substituted acylaminoacid amide derivatives (2001-03-13),
13. 6197798 - Amino-benzocycloalkane derivatives (2001-03-06),
14. 6034136 - Certain cyclic thio substituted acylaminoacid amide derivatives (2000-03-07),
15. 5736554 - Compounds having antihypertensive, cardioprotective, anti-ischemic and (1998-04-07),

Title: Exploring the Innovations of Cynthia Anne Fink

Introduction: Cynthia Anne Fink, a talented inventor hailing from Lebanon, NJ, has made significant contributions to the field of pharmaceuticals with a total of 23 patents to her name. Her groundbreaking work in the development of multicyclic compounds and modulators of G protein-coupled receptor 88 showcases her dedication to advancing the treatment of cognitive disorders.

Latest Patents: One of Fink's latest patents involves multicyclic compounds and their pharmaceutical applications in treating cognitive disorders. Another notable invention is related to modulators of G protein-coupled receptor 88, highlighting her innovative approaches in drug development.

Career Highlights: Throughout her career, Fink has been associated with renowned companies such as Novartis Ag and Rhone-Poulenc Rorer Pharmaceuticals Inc. Her tenure in these organizations provided her with the platform to drive cutting-edge research and bring novel pharmaceutical solutions to the market.

Collaborations: Fink has had the privilege of working alongside esteemed colleagues such as Alfred P. Spada and Michael R. Myers. Their collaborative efforts have undoubtedly fueled innovation and fostered a rich environment for scientific exploration.

Conclusion: Cynthia Anne Fink's remarkable journey as an inventor exemplifies a commitment to pushing the boundaries of pharmaceutical research. Her pioneering work in developing novel compounds for cognitive disorders stands as a testament to her passion for driving positive change in the healthcare industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…